ArticleDiscover oncology2025
The value of circulating methylated septin 9 in the diagnosis and prognostic assessment of gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGastric cancer (GC) is a lethal malignancy usually diagnosed at advanced stages due to limited detection methods. Invasive examinations, such as electronic gastroscopy and pathological biopsy, have limitations for large-scale screening, while existing blood biomarkers (CEA, CA19-9, CA72-4) suffer from variable sensitivity and specificity. Methylated septin 9 (mSEPT9), a promising epigenetic biomarker in other cancers, remains understudied in GC. MATERIALS AND
methodsThis retrospective study included 185 GC patients admitted to Shandong Cancer Hospital and Institute from January 2020 to December 2024. Clinical data were collected, and the levels of mSEPT9, conventional biomarkers (CEA, CA199, CA724), serum gastric function indicators (pepsinogen I [PG I], pepsinogen II [PG II], gastrin-17 [G-17]), and other indicators [cystatin S (CST4), and fecal occult blood (FOB)] were measured. Statistical analysis was performed using GraphPad Prism 9.0 and SPSS 23.0.
resultsConventional biomarkers (CEA, CA19-9, CA72-4) correlated significantly with TNM staging and metastasis. The positive mSEPT9 associated with higher CA19-9 and CA72-4 levels, and enriched in advanced GC stage. Critically, serial assessments revealed that mSEPT9 sero-conversion events were temporally coupled with fluctuations in conventional biomarkers, suggesting a potential role in monitoring treatment response and predicting prognosis. In contrast, gastric function parameters, serum CST4 and FOB showed no significant correlation with TNM staging and were not useful for adjunctive GC diagnosis.
conclusionmSEPT9 shows potential in GC diagnosis and prognosis prediction, and its combination with conventional biomarkers may improve the accuracy of GC diagnosis and prognosis assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.